BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21520170)

  • 1. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma.
    Di Tommaso L; Destro A; Fabbris V; Spagnuolo G; Laura Fracanzani A; Fargion S; Maggioni M; Patriarca C; Maria Macchi R; Quagliuolo M; Borzio M; Iavarone M; Sangiovanni A; Colombo M; Roncalli M
    Hepatology; 2011 May; 53(5):1549-57. PubMed ID: 21520170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma.
    Di Tommaso L; Destro A; Seok JY; Balladore E; Terracciano L; Sangiovanni A; Iavarone M; Colombo M; Jang JJ; Yu E; Jin SY; Morenghi E; Park YN; Roncalli M
    J Hepatol; 2009 Apr; 50(4):746-54. PubMed ID: 19231003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.
    Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z
    Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase.
    Seimiya M; Tomonaga T; Matsushita K; Sunaga M; Oh-Ishi M; Kodera Y; Maeda T; Takano S; Togawa A; Yoshitomi H; Otsuka M; Yamamoto M; Nakano M; Miyazaki M; Nomura F
    Hepatology; 2008 Aug; 48(2):519-30. PubMed ID: 18571811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
    Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
    Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.
    Anatelli F; Chuang ST; Yang XJ; Wang HL
    Am J Clin Pathol; 2008 Aug; 130(2):219-23. PubMed ID: 18628090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
    Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
    Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.
    Di Tommaso L; Franchi G; Park YN; Fiamengo B; Destro A; Morenghi E; Montorsi M; Torzilli G; Tommasini M; Terracciano L; Tornillo L; Vecchione R; Roncalli M
    Hepatology; 2007 Mar; 45(3):725-34. PubMed ID: 17326147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.
    Long J; Lang ZW; Wang HG; Wang TL; Wang BE; Liu SQ
    Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):296-305. PubMed ID: 20525558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
    Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver.
    Yoo HJ; Lee JM; Lee JY; Kim SH; Kim SJ; Han JK; Choi BI
    Invest Radiol; 2009 Dec; 44(12):800-7. PubMed ID: 19838119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
    Llovet JM; Chen Y; Wurmbach E; Roayaie S; Fiel MI; Schwartz M; Thung SN; Khitrov G; Zhang W; Villanueva A; Battiston C; Mazzaferro V; Bruix J; Waxman S; Friedman SL
    Gastroenterology; 2006 Dec; 131(6):1758-67. PubMed ID: 17087938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
    Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
    Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
    Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
    Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.
    Stroescu C; Herlea V; Dragnea A; Popescu I
    J Gastrointestin Liver Dis; 2006 Mar; 15(1):9-14. PubMed ID: 16680226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
    Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
    Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
    Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
    Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
    Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
    J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma.
    Vasuri F; Malvi D; Bonora S; Fittipaldi S; Renzulli M; Tovoli F; Golfieri R; Bolondi L; D'Errico A
    Histopathology; 2018 Feb; 72(3):414-422. PubMed ID: 28881044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.